Similar articles

• [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].

  Angiolini C. Angiolini C. Suppl Tumori. 2004 Jul-Aug;3(4):S75-6. Suppl Tumori. 2004. PMID: 15206219 Review. Italian. No abstract available.
• [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].

  Gamucci T. Gamucci T. Suppl Tumori. 2004 Jul-Aug;3(4):S16. Suppl Tumori. 2004. PMID: 15206201 Italian. No abstract available.
• [The ATAC study on adjuvants in breast cancer].

  Bravi S. Bravi S. Suppl Tumori. 2004 Jul-Aug;3(4):S15. Suppl Tumori. 2004. PMID: 15206200 Italian. No abstract available.
• Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.

  Twombly R. Twombly R. J Natl Cancer Inst. 2003 Dec 3;95(23):1738-9. doi: 10.1093/jnci/95.23.1738. J Natl Cancer Inst. 2003. PMID: 14652229 No abstract available.
• Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?

  Wu K, Brown P. Wu K, et al. J Natl Cancer Inst. 2003 Jun 4;95(11):766-7. doi: 10.1093/jnci/95.11.766. J Natl Cancer Inst. 2003. PMID: 12783921 Review. No abstract available.